
DMK Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation (DMKPQ) Cash on Hand — Cash & Short-Term Investments
Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.
DMKPQ · cash on hand · updated Dec 31, 2022
Core cash position
as of Dec 31, 2022Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.
Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD
Net cash vs debt
Cash vs Debt · Balance Sheet HealthDMK Pharmaceuticals Corporation has a net cash position of $768,870, holding more cash than debt.
Cash on hand history
Annual cash on hand by year
DMKPQ cash & short-term investments historyHealthcare Sector Cash Reserves Comparison
About cash on hand & methodology
DMK Pharmaceuticals Corporation (DMKPQ) cash on hand as of December 31, 2022 is $1.1M, comprising $1.1M in cash and cash equivalents (CCE) plus $30,068 in short-term investments — reported as DMK Pharmaceuticals Corporation cash and short-term investments on the balance sheet (10-K filing). Also referred to as DMK Pharmaceuticals Corporation cash reserves or cash position.
DMK Pharmaceuticals Corporation annual cash on hand history shows decreased -95.2% in 2022: decreased -95.2% in 2022. DMK Pharmaceuticals Corporation cash reserves in 2022 reflect the company's capital allocation strategy.
DMK Pharmaceuticals Corporation carries total debt of $342,562 against cash of $1.1M, resulting in a net cash position of +$768,870. For the full balance sheet, see the Financials → Balance Sheet tab.
Frequently asked questions
DMKPQ cash on hand · 5 questionsAs of December 31, 2022, DMK Pharmaceuticals Corporation (DMKPQ) has $1,111,432 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $1,081,364 in cash and cash equivalents (CCE) plus $30,068 in short-term investments. Latest quarter (September 30, 2023): $6,663,921. Data sourced from the annual 10-K filing via FMP.
▸ Source: FMP /balance-sheet-statement · US GAAP · DMK Pharmaceuticals Corporation · DMK Pharmaceuticals Corporation SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2022